Biocytogen Pharmaceuticals (Beijing) has entered into a strategic partnership with Sihuan Pharmaceutical Holdings Group to accelerate the development of novel antibody-based therapies across multiple disease areas.

Under the agreement, the two companies will combine Biocytogen’s advanced fully human antibody discovery platform with Sihuan Pharmaceutical’s expertise in drug development, manufacturing and commercialisation. The collaboration will focus on advancing innovative therapeutics, including those targeting weight management and other key disease segments.

Biocytogen will contribute its proprietary technologies, including target-humanised mouse models, in vivo efficacy systems and an AI-driven antibody discovery platform based on real human antibody sequences. These capabilities are expected to enhance the identification and development of high-potential drug candidates.

The partnership aims to leverage the complementary strengths of both organisations to accelerate the progression of promising molecules from early-stage research to clinical and commercial success.

Commenting on the collaboration, Dr Yuelei Shen, President and CEO of Biocytogen, said the partnership would expand efforts in developing next-generation therapeutic modalities such as bispecific and multispecific antibodies, antibody-drug conjugates (ADCs), VHHs, and T-cell receptor (TCR)-based therapies.

The alliance reflects growing industry focus on advanced biologics and precision therapies, with both companies aiming to strengthen their presence in the global biopharmaceutical innovation landscape.